信邦製藥(002390.SZ):擬以不超2.8億元參設投資基金
格隆匯7月15日丨信邦製藥(002390.SZ)公佈,公司於2017年與寧波澤泓子悦投資管理有限公司(“澤悦投資”)共同發起成立了杭州鏡心投資合夥企業(有限合夥),杭州鏡心投資合夥企業(有限合夥)先後投資多個優質的醫療大健康領域項目,其中奧精醫療(證券代碼:688613)已成功在科創板掛牌上市,另有多個投資項目正在申報境內外上市。
基於鏡心投資的良好表現,為了進一步加強合作,深化各方優勢資源共享整合,在公司產業鏈上下游尋找符合公司長期發展戰略、潛在的優質投資標的,公司擬使用自有資金不超過2.8億元與澤悦投資、海南澤悦捷翔企業管理諮詢合夥企業(有限合夥)(“海南澤悦”)及其他有限合夥人共同發起設立基金,為保障投資人利益最大化,基金分別在杭州、上海兩地設立平行基金杭州澤悦子寧創業投資合夥企業(有限合夥)、上海澤悦宜洲私募投資基金合夥企業(有限合夥)。
上述基金將聚焦於醫療服務、醫療信息化、高附加值高門檻的醫療行業前沿技術以及海外該類型技術或產品在國內商用權利、創新類生物製藥等領域,開展投資、併購、整合等業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.